434 related articles for article (PubMed ID: 19758638)
1. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638
[TBL] [Abstract][Full Text] [Related]
2. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
Freedland SJ; Partin AW; Epstein JI; Walsh PC
Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
4. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
5. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival.
Barocas DA; Salem S; Kordan Y; Herrell SD; Chang SS; Clark PE; Davis R; Baumgartner R; Phillips S; Cookson MS; Smith JA
J Urol; 2010 Mar; 183(3):990-6. PubMed ID: 20083261
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
[TBL] [Abstract][Full Text] [Related]
7. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy.
DeCastro GJ; McCann T; Benson MC; McKiernan JM
Urology; 2008 Dec; 72(6):1214-8. PubMed ID: 18597825
[TBL] [Abstract][Full Text] [Related]
8. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
9. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
11. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy.
Kordan Y; Salem S; Chang SS; Clark PE; Cookson MS; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
J Urol; 2009 Dec; 182(6):2695-701. PubMed ID: 19836759
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 May; 161(5):1525-9. PubMed ID: 10210388
[TBL] [Abstract][Full Text] [Related]
13. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
14. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
Han M; Walsh PC; Partin AW; Rodriguez R
J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
[TBL] [Abstract][Full Text] [Related]
15. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
[TBL] [Abstract][Full Text] [Related]
16. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
17. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
19. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]